Your search returned 4 results.

Results
	1.	Effects of vedolizumab, adalimumab and infliximab on biliary inflammation in individuals with primary sclerosing cholangitis and inflammatory bowel disease. [electronic resource] by Tse, C S Loftus, E V Raffals, L E Gossard, A A Lightner, A L Producer: 20190819 In: Alimentary pharmacology & therapeutics vol. 48 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	2.	Editorial: biologic therapies for primary sclerosing cholangitis-more disappointment than promise? Authors' reply. [electronic resource] by Tse, C S Loftus, E V Raffals, L E Gossard, A A Lightner, A L Producer: 20190827 In: Alimentary pharmacology & therapeutics vol. 48 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	3.	Postoperative outcomes in vedolizumab-treated Crohn's disease patients undergoing major abdominal operations. [electronic resource] by Lightner, A L McKenna, N P Tse, C S Raffals, L E Loftus, E V Mathis, K L Producer: 20190312 In: Alimentary pharmacology & therapeutics vol. 47 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	4.	Idiopathic inflammatory demyelinating disease of the central nervous system in patients with inflammatory bowel disease: retrospective analysis of 9095 patients. [electronic resource] by De Felice, K M Novotna, M Enders, F T Faubion, W A Tremaine, W J Kantarci, O H Raffals, L E Producer: 20150601 In: Alimentary pharmacology & therapeutics vol. 41 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)